Northwell Health | Strategic Alliance Partners

December 06, 2023

The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.

November 29, 2023

Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.

November 29, 2023

Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.

November 17, 2023

Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.

November 17, 2023

Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.

September 27, 2023

Wesley J. Talcott, MD, MBA, discusses the importance of de-escalating therapy in patients with breast cancer, highlighting use of personalized treatment approaches.

June 26, 2023

Francisco Javier Esteva, MD, PhD, discusses key findings from the phase 3 NATALEE trial in patients with hormone receptor–positive, HER2-negative early breast cancer.

February 05, 2023

Daniel King, MD, PhD, discusses the results of an institutional review evaluating socioeconomic factors associated with disparities for germline genetic testing in patients with pancreatic adenocarcinoma, why germline testing is necessary for thi population, and how he is addressing gaps in germline testing in his own practice.

January 31, 2023

Daniel King, MD, PhD, discusses socioeconomic disparities causing delays in germline genetic testing for patients with pancreatic cancer.

December 02, 2022

Joanna M. Rhodes, MD, discusses evaluating the unmet needs of elderly patients in CLL.

November 23, 2021

Wasif M. Saif, MD, MBBS, discusses recommendations for germline testing in patients with pancreatic cancer.

November 10, 2021

Wasif M. Saif, MD, MBBS, discusses the rationale to utilize PARP inhibitors in BRCA-mutated pancreatic cancer.

November 08, 2021

Francisco Javier Esteva, MD, PhD, discusses the clinical implications of the fixed-dose regimen comprised of subcutaneous trastuzumab and pertuzumab in the treatment of patients with HER2-positive breast cancer.

November 03, 2021

Paul Lawrence Baron, MD, discussed best practices for determining a patient’s risk of developing breast cancer, the significance of targeting HER2 in patients with early-stage and metastatic disease, and remaining questions with radiation therapy in the field.

November 02, 2021

Francisco Javier Esteva, MD, PhD, discusses therapeutic developments for patients with HER2-positive breast cancer.

November 02, 2021

Paul Lawrence Baron, MD, discusses contributing factors for developing breast cancer.

October 18, 2021

Francisco Javier Esteva, MD, PhD, discussed the current approach to treating patients with early-stage HER2-positive breast cancer, unmet needs in the space, and future directions with neratinib and T-DM1.

May 10, 2021

Nagashree Seetharamu, MD, MBBS, discusses emerging targets in non–small cell lung cancer and the limitations of current biomarkers.

May 06, 2021

Jacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions.

May 03, 2021

Jacqueline Claudia Barrientos, MD, MS, discusses factors to consider when selecting between BCL-2 inhibitors and BTK inhibitors in chronic lymphocytic leukemia.